Patents Examined by Patricia Duffy
  • Antibody drug conjugates
    Patent number: 10590165
    Abstract: There is disclosed a Dolastatin derivative, conjugated to an antibody, comprising a Dolastatin derivative moiety of Formula IV.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: March 17, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Dylan Deng, Hong Zhang
  • Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
    Patent number: 10588857
    Abstract: The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 17, 2020
    Assignee: Therabiome, LLC
    Inventors: Jerome J. Schentag, Mohan Kabadi
  • Screening for L-form bacteria
    Patent number: 10584370
    Abstract: Disclosed herein are methods for screening clinical or biological samples to determine the presence of L-form bacteria within the sample. Methods include contacting a sample to a liquid growth medium and incubating the liquid growth medium at a temperature lower than 37 degrees C. The liquid growth medium is monitored for L-form bacterial growth. An amount of the liquid growth medium is transferred as an inoculant to a solid growth medium, and the solid growth medium is incubated under conditions that maintain a hydrated state of the inoculant to enable the L-form bacteria to efficiently interface with the solid growth medium and continue to grow.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: March 10, 2020
    Assignee: Soft Cell Biological Research, LLC
    Inventor: John Brent Hunt
  • Anti-plasmodium parasite antibodies
    Patent number: 10577412
    Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: March 3, 2020
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Rolf Fendel, Stefan Barth, Rainer Fischer, Andreas Reimann, Dominika Maskus, Torsten Klockenbring
  • Anti-wall teichoic antibodies and conjugates
    Patent number: 10570192
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
    Patent number: 10548904
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 4, 2020
    Assignee: FERRING B.V.
    Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
  • culture medium
    Patent number: 10550437
    Abstract: A culture medium for culturing Clostridium difficile under aerobic culture conditions, the medium includes a nutrient medium that promotes growth of Clostridium difficile and amounts of thioglycolic and L-cystine effective to consume oxygen in the culture medium and facilitate growth of Clostridium difficile.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: February 4, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Curtis Donskey, Michelle Nerandzic, Jennifer Cadnum
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 10544194
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 28, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
    Patent number: 10537584
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: January 21, 2020
    Assignee: FERRING B.V.
    Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
  • Thixotropic processing of magnesium composites with a nanoparticles-haloed grain structure for biomedical implant applications
    Patent number: 10532134
    Abstract: In described embodiments, the present invention includes a magnesium-based composite material formed from a plurality of ?-phase magnesium grains; and a ?-alloy phase comprising magnesium and nano-diamond and/or and phosphate containing nanoparticles, the ?-alloy phase surrounding each of the plurality of magnesium grains. A method of manufacturing a composite material is also disclosed.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 14, 2020
    Assignee: Drexel University
    Inventors: Gongyao Zhou, Haibo Gong, Donggang Yao
  • Antibodies, antibody drug conjugates and methods of use
    Patent number: 10509035
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 17, 2019
    Assignee: GAMAMABS PHARMA SA
    Inventors: Olivier Dubreuil, Jean-Marc Barret, Jean-François Prost, Delphine Desigaud
  • Methods of modulating immune responses using BCMA polypeptide
    Patent number: 10494416
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 3, 2019
    Assignees: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Channelrhodopsins for optical control of cells
    Patent number: 10472398
    Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: November 12, 2019
    Assignees: Massachusetts Institute of Technology, The Governors of The University of Alberta
    Inventors: Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Gane Ka-Shu Wong, Yongku Peter Cho
  • Channelrhodopsins for optical control of cells
    Patent number: 10472399
    Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 12, 2019
    Assignees: Massachusetts Institute of Technology, The Governors of The University of Alberta
    Inventors: Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Gane Ka-Shu Wong, Yongku Peter Cho
  • Human antibodies to Hemolysin A toxin
    Patent number: 10463748
    Abstract: The present invention provides antibodies that bind to Staphylococcus aureus Hemolysin A toxin, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Hemolysin A. The antibodies of the invention are useful for inhibiting or neutralizing Hemolysin A activity, thus providing a means of preventing or treating a Hemolysin A-related disease or disorder such as S. aureus infection. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of a S. aureus infection.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: November 5, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Alida Coppi, Peter Mason, William Olson
  • Organic hydroperoxide reduction in perfumery raw materials
    Patent number: 10456339
    Abstract: The aspects presented herein provide methods and compositions for the reduction of the peroxide value of perfume ingredients, formulated perfumes, formulated body care products, formulated skin care products, formulated homecare products, essential oils, food raw materials, formulated food products, and natural extracts.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 29, 2019
    Assignee: FIRMENICH SA
    Inventors: Michael J. Calandra, Ying Wang
  • Oral care composition
    Patent number: 10441516
    Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 15, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Venda Porter, Andre Morgan, Michael Prencipe, Sarita Mello
  • Preparation of high-purity gadobutrol
    Patent number: 10435417
    Abstract: A process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration is described. The process is carried out using specifically controlled crystallization conditions.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 8, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Intravaginal ring drug delivery system
    Patent number: 10413504
    Abstract: Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wouter de Graaff, Willy J. H. Verhoeven
  • Site-specific conjugation of linker drugs to antibodies and resulting ADCs
    Patent number: 10407743
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumors and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 10, 2019
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans